Patent · US Active

Deuterated fezolinetant

US11078203B2 · kind B2 · utility

0Cited by

0References

9Claims

0Family size

Assignee

Ogeda SA · BE

Inventor

Hamid R. Hoveyda · Brussels, BE

Key dates

Filing date	Jul 12, 2018
Grant date	Aug 3, 2021
Priority date	—
Expiry date	Aug 3, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07B2200/05
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Deuterated fezolinetant (R)-(4-fluorophenyl)-(8-methyl-3-(3-(methyl-d3)-1,2,4-thiadiazol-5-yl)-5,6-dihydro-[1,2,4]trizolo[4,3-a]pyrazin-7(8H)-yl)methanone: or a pharmaceutically acceptable salt or solvate thereof, as an NK-3 antagonist. Also, methods of modulating NK-3 receptor activity including administering an effective amount of the compound or pharmaceutically acceptable salt or solvate thereof. Additionally, a process for manufacturing the compound or pharmaceutically acceptable salt or solvate thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.